202 related articles for article (PubMed ID: 34264955)
1. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
Chang LS; Oblinger JL; Smith AE; Ferrer M; Angus SP; Hawley E; Petrilli AM; Beauchamp RL; Riecken LB; Erdin S; Poi M; Huang J; Bessler WK; Zhang X; Guha R; Thomas C; Burns SS; Gilbert TSK; Jiang L; Li X; Lu Q; Yuan J; He Y; Dixon SAH; Masters A; Jones DR; Yates CW; Haggarty SJ; La Rosa S; Welling DB; Stemmer-Rachamimov AO; Plotkin SR; Gusella JF; Guinney J; Morrison H; Ramesh V; Fernandez-Valle C; Johnson GL; Blakeley JO; Clapp DW;
PLoS One; 2021; 16(7):e0252048. PubMed ID: 34264955
[TBL] [Abstract][Full Text] [Related]
2. Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma.
Burns SS; Chang LS
Methods Mol Biol; 2016; 1427():59-72. PubMed ID: 27259921
[TBL] [Abstract][Full Text] [Related]
3. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.
; Allaway R; Angus SP; Beauchamp RL; Blakeley JO; Bott M; Burns SS; Carlstedt A; Chang LS; Chen X; Clapp DW; Desouza PA; Erdin S; Fernandez-Valle C; Guinney J; Gusella JF; Haggarty SJ; Johnson GL; La Rosa S; Morrison H; Petrilli AM; Plotkin SR; Pratap A; Ramesh V; Sciaky N; Stemmer-Rachamimov A; Stuhlmiller TJ; Talkowski ME; Welling DB; Yates CW; Zawistowski JS; Zhao WN
PLoS One; 2018; 13(6):e0197350. PubMed ID: 29897904
[TBL] [Abstract][Full Text] [Related]
4. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas.
Mérel P; Hoang-Xuan K; Sanson M; Moreau-Aubry A; Bijlsma EK; Lazaro C; Moisan JP; Resche F; Nishisho I; Estivill X
Genes Chromosomes Cancer; 1995 Jul; 13(3):211-6. PubMed ID: 7669741
[TBL] [Abstract][Full Text] [Related]
5. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
[TBL] [Abstract][Full Text] [Related]
6. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
[TBL] [Abstract][Full Text] [Related]
7. Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.
Bassiri K; Ferluga S; Sharma V; Syed N; Adams CL; Lasonder E; Hanemann CO
EBioMedicine; 2017 Feb; 16():76-86. PubMed ID: 28126595
[TBL] [Abstract][Full Text] [Related]
8. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
[TBL] [Abstract][Full Text] [Related]
9. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
10. Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.
Waldt N; Scharnetzki D; Kesseler C; Kirches E; Stroscher N; Böhmer FD; Mawrin C
J Neurol Sci; 2020 Jan; 408():116553. PubMed ID: 31715329
[TBL] [Abstract][Full Text] [Related]
11. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
[TBL] [Abstract][Full Text] [Related]
12. Group I Paks as therapeutic targets in NF2-deficient meningioma.
Chow HY; Dong B; Duron SG; Campbell DA; Ong CC; Hoeflich KP; Chang LS; Welling DB; Yang ZJ; Chernoff J
Oncotarget; 2015 Feb; 6(4):1981-94. PubMed ID: 25596744
[TBL] [Abstract][Full Text] [Related]
13. Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults.
Pathmanaban ON; Sadler KV; Kamaly-Asl ID; King AT; Rutherford SA; Hammerbeck-Ward C; McCabe MG; Kilday JP; Beetz C; Poplawski NK; Evans DG; Smith MJ
JAMA Neurol; 2017 Sep; 74(9):1123-1129. PubMed ID: 28759666
[TBL] [Abstract][Full Text] [Related]
14. The neurofibromatosis type 2 gene is inactivated in schwannomas.
Twist EC; Ruttledge MH; Rousseau M; Sanson M; Papi L; Merel P; Delattre O; Thomas G; Rouleau GA
Hum Mol Genet; 1994 Jan; 3(1):147-51. PubMed ID: 8162016
[TBL] [Abstract][Full Text] [Related]
15. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
16. Inherited genetic syndromes and meningiomas.
Look A; Lonser RR
Handb Clin Neurol; 2020; 169():121-129. PubMed ID: 32553283
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1.
Troutman S; Moleirinho S; Kota S; Nettles K; Fallahi M; Johnson GL; Kissil JL
Oncotarget; 2016 Aug; 7(34):54515-54525. PubMed ID: 27363027
[TBL] [Abstract][Full Text] [Related]
18. NF2 tumor suppressor gene: a comprehensive and efficient detection of somatic mutations by denaturing HPLC and microarray-CGH.
Szijan I; Rochefort D; Bruder C; Surace E; Machiavelli G; Dalamon V; Cotignola J; Ferreiro V; Campero A; Basso A; Dumanski JP; Rouleau GA
Neuromolecular Med; 2003; 3(1):41-52. PubMed ID: 12665675
[TBL] [Abstract][Full Text] [Related]
19. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
20. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
Beauchamp RL; James MF; DeSouza PA; Wagh V; Zhao WN; Jordan JT; Stemmer-Rachamimov A; Plotkin SR; Gusella JF; Haggarty SJ; Ramesh V
Oncotarget; 2015 Jul; 6(19):16981-97. PubMed ID: 26219339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
